Circio Holding ASA – Exercise of Warrants by primary insider
Oslo, Norway 11 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period").
Thomas Birkballe Hansen, Chief Technology Officer of Circio, has on 10 December 2024 exercised a total of 46,800 Warrants, for the allocation of 46,800 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Thomas Birkballe Hansen in connection with the Rights Issue completed in July 2024.
A total of 13,864,852 warrants (the “Warrants”) were issued and registered with the Norwegian Register of Business Enterprises on 26 July 2024 in relation to the rights issue completed in July 2024. Each Warrant gives the holder a right to subscribe for one new share in the Company at an exercise price per share of NOK 0.60 during the exercise period (the "New Shares").
Please see further details about the transactions in the attached form.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.